Compare Aptiv PLC (APTV) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Quest Diagnostics Inc — how do they compare? Aptiv PLC trades at $48.35 (market cap $10.30B), while Quest Diagnostics Inc trades at $238.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 2.5× Aptiv PLC's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | DGX | |
|---|---|---|
Market Cap | $10.30B | $26.21B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $238.50 |
52-Week Low | $46.30 | $173.49 |
Enterprise Value | $15.23B | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $48.26, down 3.11% amid bearish technical signals and lowered 2026 guidance. Despite beating Q2 earnings estimates with $1.63 EPS versus $1.42 expected, the company faces China demand weakness and program delays. Valuation metrics appear attractive with P/E of 22.45 and P/S of 0.52, while analyst consensus remains strongly bullish with 63.6% buy ratings and $70.09 price target.
Near-term execution risks and cash flow pressures create uncertainty, but the stock's discounted valuation and consistent earnings beats offer potential upside for patient investors. The key challenge remains navigating China market softness and delayed program launches while maintaining margin improvements.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
